Virus injection takes on tough tumors in early trial

NCT ID NCT06368921

Recruiting now Disease control Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a modified virus called VRT106, which is injected directly into tumors to kill cancer cells. It involves 30 adults with advanced solid tumors that haven't responded to standard treatments. The main goal is to check safety and find the best dose, while also looking at how the virus spreads and whether it helps fight the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VRT106 (a modified virus that targets and kills cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that haven't responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so safety and dosing are still being figured out. It may not shrink tumors or work for everyone, and there could be side effects from the virus or injection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Affiliated Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, Shandong, China
Affiliated Cancer Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.